Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature.
epidermolysis bullosa
genodermatosis
inflammation
skin cancer
squamous cell carcinoma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
17 04 2022
17 04 2022
Historique:
received:
11
03
2022
revised:
12
04
2022
accepted:
15
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Epidermolysis bullosa (EB) is a group of rare congenital diseases caused by mutations in structural proteins of the dermal/epidermal junction that are characterized by extreme epithelial fragility, which determines the formation of bullae and erosions either spontaneously or after local mechanical traumas. In EB patients, skin fragility leads to many possible complications and comorbidities. One of the most feared complications is the development of cutaneous squamous cell carcinomas (SCCs) that particularly in the dystrophic recessive EB subtype can be extremely aggressive and often metastatic. SCCs in EB patients generally arise more often in the extremities, where chronic blisters and scars are generally located. SCCs represent a big therapeutic challenge in the EB population. No standard of care exists for the treatment of SCC in these patients, and therapy is based on small case studies. Moreover, the pathogenesis of cSCC in EB patients is still unclear. Many theories have been indeed postulated in order to explain why cSCC behaves so much more aggressively in EB patients compared to the general population. cSCC in EB seems to be the result of many complex interactions among cancer cells, skin microenvironment, susceptibility to DNA mutations and host immune response. In this review, we analyze the different pathogenetic mechanisms of cSCC in EB patients, as well as new therapies for this condition.
Identifiants
pubmed: 35456044
pii: cells11081365
doi: 10.3390/cells11081365
pmc: PMC9027730
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Cell Sci. 2009 Jun 1;122(Pt 11):1788-99
pubmed: 19435799
Clin Transl Oncol. 2019 Nov;21(11):1573-1577
pubmed: 30864020
Matrix Biol. 2017 Nov;63:1-10
pubmed: 28126522
Orphanet J Rare Dis. 2016 Aug 20;11(1):117
pubmed: 27544590
J Invest Dermatol. 2007 Oct;127(10):2438-44
pubmed: 17495952
Br J Dermatol. 2014 Jun;170(6):1256-65
pubmed: 24641191
Exp Dermatol. 2007 Jun;16(6):465-7
pubmed: 17518985
JAMA Dermatol. 2020 Jun 1;156(6):708-710
pubmed: 32320041
BMJ Case Rep. 2021 Feb 26;14(2):
pubmed: 33637494
Nat Rev Dis Primers. 2020 Sep 24;6(1):78
pubmed: 32973163
J Am Acad Dermatol. 2004 Apr;50(4):563-71
pubmed: 15034505
Cancer Res. 2012 Jul 15;72(14):3522-34
pubmed: 22564523
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1707-1714
pubmed: 31692111
J Natl Cancer Inst. 2015 Oct 16;108(1):
pubmed: 26476432
Dermatol Ther. 2020 Nov;33(6):e14093
pubmed: 32720460
Autoimmun Rev. 2019 Aug;18(8):786-795
pubmed: 31181325
Clin Dermatol. 2012 Jan-Feb;30(1):60-9
pubmed: 22137228
J Invest Dermatol. 2021 Apr;141(4):942-946
pubmed: 33069729
Orphanet J Rare Dis. 2010 May 28;5:12
pubmed: 20507631
J Invest Dermatol. 2018 May;138(5):1197-1200
pubmed: 29203361
Int J Mol Sci. 2020 Feb 20;21(4):
pubmed: 32093196
Sci Transl Med. 2018 Aug 22;10(455):
pubmed: 30135250
Orphanet J Rare Dis. 2019 Dec 3;14(1):278
pubmed: 31796084
Acta Derm Venereol. 2021 Aug 24;101(8):adv00523
pubmed: 34230977
Clin Cancer Res. 2019 Jun 1;25(11):3384-3391
pubmed: 30846478
Eur J Dermatol. 2015 Apr;25 Suppl 1:30-2
pubmed: 26083672
Int J Mol Sci. 2021 May 12;22(10):
pubmed: 34065916
Br J Dermatol. 2016 Jan;174(1):56-67
pubmed: 26302137
Acta Derm Venereol. 2018 Jan 12;98(1):70-76
pubmed: 28853495
Anal Cell Pathol (Amst). 2011;34(6):339-53
pubmed: 22002724
Int Wound J. 2020 Apr;17(2):519-521
pubmed: 31944565
J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1195-6
pubmed: 25758658
Br J Dermatol. 2005 Sep;153(3):672-4
pubmed: 16120168
Life (Basel). 2022 Jan 30;12(2):
pubmed: 35207500
Am J Clin Dermatol. 2002;3(6):371-80
pubmed: 12113646
Exp Dermatol. 2019 Oct;28(10):1176-1189
pubmed: 31140655
Br J Dermatol. 2010 Oct;163(4):726-35
pubmed: 20586780
Br J Dermatol. 2008 Apr;158(4):778-85
pubmed: 18284387
Br J Dermatol. 2020 Mar;182(3):530-531
pubmed: 31486079
Int J Mol Sci. 2019 Nov 14;20(22):
pubmed: 31739489
J Am Acad Dermatol. 2009 Feb;60(2):203-11
pubmed: 19026465
J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S82-5
pubmed: 9703130
Dermatol Pract Concept. 2018 Jul 31;8(3):227-230
pubmed: 30116669
Dermatol Clin. 2010 Jan;28(1):23-32
pubmed: 19945613
Br J Dermatol. 2021 Apr;184(4):697-708
pubmed: 32726455